Analysts/Institutional Investor Meet/Con. Call Updates

12th August, 2026 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No. : 540701 (Equity) Ref. : (i) Symbol – DCAL : 975834, 976560, 977467 and 977859 (Debt) (ii) Series – EQ SUB: INTIMATION OF CONFERENCE CALL Dear Sir, This is to inform that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Company has arranged Conference Call with Investors on Monday, 17th August, 2026 at 17:00 hrs. (IST) to discuss the financial result and performance of the Company for the first quarter ended on 30th June, 2026. The details of Conference Call are attached herewith. Kindly take the same on your record. Thanking You, Yours faithfully, For, Dishman Carbogen Amcis Limited Shrima Dave Company Secretary Encl.: As Above Dishman Carbogen Amcis Limited to announce its Q1FY27 results on 14 Aug 2026. The management of the company to host Q1FY27 Earnings Conference Call on 17 Aug 2026 at 17:00hrs - 18:00hrs, IST Primary Numbers International Toll-Free Numbers 086 3416 8589 / USA - 18773870849 Singapore - 8001011941 086 4536 7374 UK - 08000163439 Hong Kong - 800903171 International Participation PIN No.: 8630176# Pre-Registration Facility (Express Join with DiamondPassTM Click Here to pre-register for the call and dial to avoid long queue and save time) in directly without waiting for the operator. Management Represented by: Mr. Harshil Dalal Mr. Stephan Fritschi Global CFO Chief Executive Officer, Carbogen Amcis Entities About Dishman Carbogen Amcis Limited Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late-stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China. The company provides end-to-end integrated high-value niche CDMO offering and has comprehensive product offerings which include APIs, High Potent APIs, Intermediates, Phase Transfer Catalysts, Vitamin D Analogues, Cholesterol, Lanolin-related products, Antiseptic and Disinfectant formulations. For details, please visit www.imdcal.com. For details please contact: Harshil Dalal Krishna Patel Global CFO Ernst & Young LLP P: +91 22 22867597 P: +91 9998236402 E: harshil.dalal@dishmangroup.com E: krishna.patel2@in.ey.com